OrbiMed’s Akero Therapeutics AKRO Stock Holding History

OrbiMed’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-526,200	Closed	-$25M	–	109
2025 Q3	$25M	Buy	526,200 +314,900	+149%	+$15.2M	0.59%	49
2025 Q2	$11.3M	Buy	211,300 +31,400	+17%	+$1.43M	0.28%	57
2025 Q1	$7.28M	Buy	179,900 +113,900	+173%	+$4.83M	0.17%	72
2024 Q4	$1.84M	Buy	+66,000	New	+$2M	0.04%	104
2023 Q4	–	Sell	-350,000	Closed	-$17.7M	–	112
2023 Q3	$17.7M	Buy	350,000 +150,500	+75%	+$7.01M	0.38%	66
2023 Q2	$9.31M	Buy	+199,500	New	+$9.14M	0.17%	90

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

OrbiMed's AKRO Position: Q4 2025 in Review

OrbiMed sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 526,200 shares — an estimated $25M sold.

OrbiMed first reported a position in AKRO in Q2 2023 and held it in 6 quarters. The position peaked at $25M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

OrbiMed reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
OrbiMed sold 526,200 Akero Therapeutics shares in Q4 2025, an estimated $25M.
OrbiMed first reported a position in Akero Therapeutics in Q2 2023 and held it in 6 quarters.
OrbiMed's Akero Therapeutics position peaked at $25M in Q3 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on OrbiMed's 13F filing for Q4 2025, filed 17 Feb 2026.